US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust Dorsey Wright Dynamic Focus 5 ETF

37.88

-0.3500-0.92%

Post-market: 37.86-0.0200-0.05%16:04 EST

Volume:5.83K

Turnover:221.96K

Market Cap:106.06M

PE:- -

High:38.22

Open:38.19

Low:37.88

Close:38.23

52wk High:39.06

52wk Low:31.90

Shares:2.80M

Float Shares:2.80M

Volume Ratio:0.96

T/O Rate:0.21%

Dividend:0.94

Dividend Rate:2.47%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Why Is Rein Therapeutics Stock Trading Higher On Monday?

Benzinga_recent_news

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

Phase III Clinical Trial Failure Sends Company Stock Plummeting 83%

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

Why Is United Therapeutics Stock Rallying On Tuesday?

Benzinga_recent_news

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/FVC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FVC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FVC\",,,,,undefined,":{"symbol":"FVC","market":"US","secType":"STK","nameCN":"First Trust Dorsey Wright Dynamic Focus 5 ETF","latestPrice":37.88,"timestamp":1770757200000,"preClose":38.23,"halted":0,"volume":5827,"hourTrading":{"tag":"盘后","latestPrice":37.86,"preClose":37.88,"latestTime":"16:04 EST","volume":5,"amount":189.47,"timestamp":1770757477768,"change":-0.02,"changeRate":-0.000528,"amplitude":0},"delay":0,"changeRate":-0.009155113784985465,"floatShares":2800002,"shares":2800002,"eps":0,"marketStatus":"Post-Mkt","change":-0.35,"latestTime":"02-10 16:07:43 EST","open":38.19,"high":38.22,"low":37.88,"amount":221956.3713,"amplitude":0.008894,"askPrice":41.34,"askSize":100,"bidPrice":34.58,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770771600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":38.23,"sharesOutstanding":2800002,"nav":38.09,"aum":106652076.18,"dividendRate":0.024725,"bidAskSpread":0.004725,"postHourTrading":{"tag":"盘后","latestPrice":37.86,"preClose":37.88,"latestTime":"16:04 EST","volume":5,"amount":189.47,"timestamp":1770757477768,"change":-0.02,"changeRate":-0.000528,"amplitude":0},"volumeRatio":0.955685},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FVC\",,,,,undefined,":{"symbol":"FVC","floatShares":2800002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.955685,"shares":2800002,"dividePrice":0.9366,"high":38.22,"amplitude":0.008894,"preClose":38.23,"low":37.88,"week52Low":31.9,"pbRate":"--","week52High":39.055,"institutionHeld":0,"latestPrice":37.88,"eps":0,"divideRate":0.024725,"volume":5827,"delay":0,"ttmEps":0,"open":38.19,"prevYearClose":36.368,"prevWeekClose":38.14,"prevMonthClose":38.29,"prevQuarterClose":36.368,"fiveDayClose":38.2668,"twentyDayClose":38.205,"sixtyDayClose":36.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FVC\",params:#limit:5,,,undefined,":[{"date":"2025-12-12","symbol":"FVC","amount":0.3232,"announcedDate":"2025-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-12","defaultRemindTime":1765549800000,"name":"First Trust Dorsey Wright Dynamic Focus 5 ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-12","currency":"USD","dateTimestamp":1765515600000,"payDate":"2025-12-31"},{"date":"2025-09-25","symbol":"FVC","amount":0.2262,"announcedDate":"2025-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-25","defaultRemindTime":1758807000000,"name":"First Trust Dorsey Wright Dynamic Focus 5 ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-25","currency":"USD","dateTimestamp":1758772800000,"payDate":"2025-09-30"},{"date":"2025-06-26","symbol":"FVC","amount":0.2677,"announcedDate":"2025-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-26","defaultRemindTime":1750944600000,"name":"First Trust Dorsey Wright Dynamic Focus 5 ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-30","payableDate":"2025-06-26","currency":"USD","dateTimestamp":1750910400000,"payDate":"2025-06-30"},{"date":"2025-03-27","symbol":"FVC","amount":0.1174,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"First Trust Dorsey Wright Dynamic Focus 5 ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-03-31"},{"date":"2024-12-13","symbol":"FVC","amount":0.0275,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust Dorsey Wright Dynamic Focus 5 ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FVC\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-21","recordDate":"2016-09-23","paymentDate":"2016-09-30","value":0.0365,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2016-12-30","value":0.0068,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2016-12-30","value":0.1017,"currency":"USD"},{"executeDate":"2017-06-22","recordDate":"2017-06-26","paymentDate":"2017-06-30","value":0.0169,"currency":"USD"},{"executeDate":"2017-09-21","recordDate":"2017-09-22","paymentDate":"2017-09-29","value":0.0459,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FVC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FVC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606712430","title":"GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712430","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606712430?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:45","pubTimestamp":1769607900,"startTime":"0","endTime":"0","summary":"Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan.  28, 2026  (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3227630/0/en/GRI-Bio-Delivers-Compelling-New-Phase-2a-Gene-Expression-Data-Demonstrating-Improvements-in-Key-Drivers-of-Fibrosis-and-Lung-Repair-in-IPF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","FVC","GRI"],"gpt_icon":0},{"id":"2590473558","title":"GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590473558","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590473558?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400700,"startTime":"0","endTime":"0","summary":"Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203497/0/en/GRI-Bio-Announces-Positive-Topline-Data-from-its-Phase-2a-Study-in-Idiopathic-Pulmonary-Fibrosis-IPF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4007","BK4218","BK4139","FVC","BK4181","PK"],"gpt_icon":0},{"id":"2580524942","title":"Why Is Rein Therapeutics Stock Trading Higher On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2580524942","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580524942?lang=en_us&edition=fundamental","pubTime":"2025-11-04 02:17","pubTimestamp":1762193820,"startTime":"0","endTime":"0","summary":"Rein Therapeutics shares rise after the FDA lifts clinical hold on its Phase 2 RENEW trial for idiopathic pulmonary fibrosis treatment LTI-03.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/03/medical-research-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/03/medical-research-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/11/48600068/why-is-rein-therapeutics-stock-trading-higher-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/11/48600068/why-is-rein-therapeutics-stock-trading-higher-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["RNTX","LENZ","BK4007","BK4139","FVC","BK4539"],"gpt_icon":0},{"id":"2580290030","title":"Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2580290030","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580290030?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:30","pubTimestamp":1762173000,"startTime":"0","endTime":"0","summary":"FDA lifts clinical hold following review of Company’s Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179135/28652/en/Rein-Therapeutics-Receives-FDA-Clearance-to-Resume-U-S-Phase-2-Trial-of-LTI-03-in-Idiopathic-Pulmonary-Fibrosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","RNTX","FVC","LENZ","BK4007"],"gpt_icon":0},{"id":"2578480766","title":"BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2578480766","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578480766?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562800,"startTime":"0","endTime":"0","summary":"- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174417/0/en/BridgeBio-Reports-Positive-Phase-3-Results-for-Small-Molecule-BBP-418-in-LGMD2I-R9-FORTIFY-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBP","EMA","BK4081","FVC"],"gpt_icon":0},{"id":"2575328444","title":"Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks","url":"https://stock-news.laohu8.com/highlight/detail?id=2575328444","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575328444?lang=en_us&edition=fundamental","pubTime":"2025-10-14 02:23","pubTimestamp":1760379780,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/13/Medical--Research-And-Scientist-In-Labor_0.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/13/Medical--Research-And-Scientist-In-Labor_0.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/10/48184263/tvardi-therapeutics-lung-disease-candidate-fails-to-show-any-clinical-benefit-stock-sinks","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48184263/tvardi-therapeutics-lung-disease-candidate-fails-to-show-any-clinical-benefit-stock-sinks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LENZ","BK4139","TVRD","BK4539","FVC","BK4007"],"gpt_icon":0},{"id":"1109831044","title":"Phase III Clinical Trial Failure Sends Company Stock Plummeting 83%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831044","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109831044?lang=en_us&edition=fundamental","pubTime":"2025-09-17 14:04","pubTimestamp":1758089069,"startTime":"0","endTime":"0","summary":"Recently, aTyr Pharma announced top-line results from its Phase III EFZO-FIT™ trial evaluating Efzofitimod for the treatment of pulmonary sarcoidosis. The trial results showed that Efzofitimod failed...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCS","FVC","BK4007"],"gpt_icon":0},{"id":"2567411931","title":"aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2567411931","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567411931?lang=en_us&edition=fundamental","pubTime":"2025-09-15 19:30","pubTimestamp":1757935800,"startTime":"0","endTime":"0","summary":"Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/15/3149882/0/en/aTyr-Pharma-Announces-Topline-Results-from-Phase-3-EFZO-FIT-Study-of-Efzofitimod-in-Pulmonary-Sarcoidosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FVC","OCS"],"gpt_icon":0},{"id":"2565959684","title":"New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM","url":"https://stock-news.laohu8.com/highlight/detail?id=2565959684","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565959684?lang=en_us&edition=fundamental","pubTime":"2025-09-08 21:00","pubTimestamp":1757336400,"startTime":"0","endTime":"0","summary":"Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti + OpfoldaPRINCETON, N.J., Sept.  08, 2025  (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/08/3146157/15991/en/New-4-Year-Data-for-Pombiliti-cipaglucosidase-alfa-atga-Opfolda-miglustat-Presented-at-ICIEM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MMT","GAA","FVC"],"gpt_icon":0},{"id":"2564138506","title":"Why Is United Therapeutics Stock Rallying On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2564138506","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564138506?lang=en_us&edition=fundamental","pubTime":"2025-09-02 22:59","pubTimestamp":1756825140,"startTime":"0","endTime":"0","summary":"United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/02/United-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/02/United-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/25/09/47451902/why-is-united-therapeutics-stock-rallying-on-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/25/09/47451902/why-is-united-therapeutics-stock-rallying-on-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","LU1571399168.USD","UTHR","BK4532","LU1699723380.USD","FVC"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}